Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page
- CheckyesterdayChange DetectedA new platform revision label Revision: v3.5.4 was added, replacing the previous Revision: v3.5.3. This indicates a backend deployment update with no change to the page content or study details.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check30 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check95 days agoChange DetectedRevision: v3.4.2 was added, and the prior government funding status notice (v3.4.1) was removed. The core study details and data remain unchanged.SummaryDifference0.4%

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.